Encompass Health EHC
NYSE EHC
$121.61 -0.10 (-0.08%)
As of: Oct 20, 2026 · 3:59 PM EDT

Encompass Health (EHC) Receivables - Other (2011 - 2018)

Updated

Encompass Health's Receivables - Other came in at $15.5 million for Q2 2018, unchanged from $15.5 million a year earlier and unchanged from the prior quarter.

Analysis

Encompass Health (EHC) Receivables - Other (2011 - 2018) Analysis & Trends

Going back to Q4 2011, Encompass Health's Receivables - Other data covers 10 quarters.

  • Going back by year, Receivables - Other was $15 million in FY2016.
  • Year-over-year, Receivables - Other increased in four of the last five quarters, with growth averaging 2.7%.
  • Business Quant data shows EHC's Receivables - Other at $15.5 million (Q1 2018), $15.5 million (Q4 2017) and $15.5 million (Q3 2017) in the three quarters before Q2 2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 HCA Healthcare 102.50 Bn 98.51 Bn -
2 Natera 58.05 Bn 53.74 Bn 485.19 Mn
3 Labcorp Holdings 26.39 Bn 24.13 Bn 1.11 Bn
4 Quest Diagnostics 26.28 Bn 24.41 Bn 1.03 Bn
5 Tenet Healthcare 22.71 Bn 11.72 Bn -
6 Guardant Health 21.59 Bn 17.65 Bn 219.03 Mn
7 BrightSpring Health Services 12.87 Bn 11.21 Bn 492.75 Mn
8 Fresenius Medical Care AG 12.49 Bn 4.44 Bn 1.52 Bn
9 Encompass Health 12.04 Bn 11.70 Bn -
10 Tempus AI 12.03 Bn 9.06 Bn 246.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2018 15.50 Mn
Mar 31, 2018 15.50 Mn
Dec 31, 2017 15.50 Mn
Sep 30, 2017 15.50 Mn
Jun 30, 2017 15.50 Mn
Mar 31, 2017 15.00 Mn
Dec 31, 2016 15.00 Mn
Sep 30, 2016 15.00 Mn
Jun 30, 2016 15.00 Mn
Dec 31, 2011 7.70 Mn
API Access

Encompass Health Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=EHC&period=max&api_key=YOUR_API_KEY